Genetic Technologies to provide Corporate & Strategic Update at 2020 Biotech Showcase
January 13 2020 - 9:00AM
Genetic Technologies (ASX: GTG; NASDAQ: GENE), a leader in the
development of genetic risk assessment tests, recently announced
the commercial availability and US launch of the company’s GeneType
for Breast Cancer in 20 centers across eight States.
GeneType for Breast Cancer is the world’s first
genomic test to accurately predict risk of disease by combining the
information contained in DNA with family history and mammography
data to create a powerful new tool in the battle with breast
cancer. The company is actively seeking commercial partners for
distribution throughout the United States.
“GeneType for Breast Cancer is the first of a
number of different validated risk assessment tools representing
the next generation of disease prediction,” said Dr. George
Muchnicki, CEO of Genetic Technologies. “We look forward to
building on existing channels and establishing partnerships aimed
at commercializing the future of preventative medicine.”
The company recently announced the full
commissioning of its Australian laboratory enabling sales of
GeneType for Breast Cancer. According to Dr. Muchnicki, “We are now
well positioned to respond to the pre-market interest in
GeneType.”
CORPORATE UPDATE &
PRESENTATION
Company leadership will be providing additional
details regarding the GeneType for Breast Cancer launch and other
company initiatives at the upcoming 2020 Biotech Showcase in San
Francisco, California. Genetic Technologies management will be
presenting on January 14th at 2:30PM (presentation room
Franciscan). For additional details, please visit www.gtglabs.com
and/or contact Dr. George Muchnicki, CEO, Genetic Technologies
(George.muchnicki@gtglabs.com).
Dr George MuchnickiActing CEO and Justyn
Stedwell Company SecretaryOn behalf of the Board of
DirectorsGenetic Technologies Limited13 January 2020
About Genetic Technologies Limited
Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a
diversified molecular diagnostics company. GTG offers cancer
predictive testing and assessment tools to help physicians
proactively manage patient health. The Company’s lead products
GeneType for Breast Cancer for non-hereditary breast cancer and
GeneType for Colorectal Cancer are clinically validated risk
assessment tests and are first in class.
Genetic Technologies is developing a pipeline of risk assessment
products.
For more information, please visit www.gtglabs.com
Investor Relations and Media (US)Dave Gentry,
CEORedChip CompaniesOffice: 1 800 RED CHIP (733 2447)Cell: US 407
491 4498dave@redchip.com
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genetic Technologies (NASDAQ:GENE)
Historical Stock Chart
From Sep 2023 to Sep 2024